Abnormal expression and function of Dectin-1 receptor in type 2 diabetes mellitus patients with poor glycemic control (HbA1c>8%)
Cortez–Espinosa N et al. – The data indicate that Dectin–1 may be involved in the abnormal immune responses that are observed in patients with T2D.
Dectin–1 expression was analyzed by flow cytometry and RT–PCR in monocytes and lymphocyte subpopulations from T2D patients (n=34) and healthy subjects (n=29).
Functional assays were used to assess cytokine synthesis, ROS levels and oxidative stress ratio.
The authors found increased expression (MFI) of Dectin–1 in monocytes from T2D patients.
Significantly higher Dectin–1 expression was also detected in CD4+ T, CD8+ T, B cells and NK cells from T2D patients compared to controls.
In contrast, monocytes from T2D patients with poor glycemic control (HbA1c>8%) showed a diminished percentage of Dectin–1+/TLR2+ cells.
Negative correlations between the percent of Dectin–1+/TLR2+ cells and fasting plasma glucose levels (FPG) and HbA1c levels were found.
A significant reduction in basal levels of IL–10 was observed in patients with poor glycemic control (HbA1c>8%) compared to patients with appropriate glycemic control (HbA1c≤6.5%) and healthy controls, an effect that was not observed in monocytes stimulated with zymosan.
Higher ROS levels in zymosan–stimulated cells from patients with poor glycemic control positively correlated with FPG levels, and the oxidative stress ratio was higher in T2D cells compared with controls.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.